News

  • 22 December 2016

    The Board of Directors of Sequana Medical AG ("Sequana Medical" or the "Company") announces with great sadness, the sudden death of its Founder, President and Chief Executive Officer, Noel L. Johnson, Ph. D.

  • 22 December 2016

    Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in the first quarter of 2017, Genkyotex’s shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex’s shareholders will hold 80% of Genticel’s share capital and voting rights (on a non-diluted basis).

  • 12 December 2016

    Sonendo, Inc., the developer of a breakthrough technology for dentistry, announced today it has completed an equity financing totaling $35 million through new and existing investors.  The financing round led by DiNovA Capital will allow Sonendo to advance the commercialization of its GentleWave® System as an alternative to standard root canal treatment and develop additional products in adjacent verticals to leverage its Multisonic Ultracleaning™ technology platform. 

  • 6 December 2016

    Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal dysfunction, announced today that the first Fecal Incontinence patients were successfully implanted at the University Hospital Southampton NHS Foundation Trust in Southampton, United Kingdom.

  • 6 December 2016

    Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform To Sienna’s Growing Pipeline.